| ²é¿´: 285 | »Ø¸´: 1 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
abcd888898Òø³æ (ÕýʽдÊÖ)
|
[½»Á÷]
¡¾×ªÌû¡¿Novo Nordisk receives approval for Victoza® in Japan
|
||
|
Novo Nordisk receives approval for Victoza® in Japan (20 January 2010) Read in PDF format Novo Nordisk receives approval for Victoza® in Japan Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Victoza® for the treatment of type 2 diabetes. Victoza® is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan, developed for the treatment of type 2 diabetes. Victoza® is indicated as monotherapy or as an add-on to sulphonylurea (SU) in people with type 2 diabetes. "The Japanese approval of Victoza® represents a major advancement in the treatment of type 2 diabetes and an important milestone for Novo Nordisk." says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We are excited to pioneer the GLP-1 market in Japan, where we are convinced Victoza® will prove to be a valuable treatment option for people with type 2 diabetes. The clinical studies conducted in Japan showed Victoza® to provide superior glucose control with a low risk of hypoglycaemia." Novo Nordisk expects to launch Victoza® in Japan in the first half of 2010 upon completion of price negotiations. |
» ²ÂÄãϲ»¶
SPguide®£ºÐ¡ÊóÌåÄÚÆ¢ÔàתȾµÄÒ»¼ü½â¾ö·½°¸
ÒѾÓÐ0È˻ظ´
¸ßЧ·Î°ÐÏòRNAתȾ£¬¼ÓËٷβ¿RNAÒ©Î↑·¢
ÒѾÓÐ2È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ178È˻ظ´
¶þÌǵÄÌÇÖ¬£¬ºÏ³Éºósephadex LH-20·ÖÀë²»³öÀ´£¬ÇóÖú
ÒѾÓÐ1È˻ظ´
ÄÏ·½Ò½¿Æ´óѧÖé½Ò½ÔºÐ¤¼ÆÉú¿ÎÌâ×éÕÐÊÕ²©Ê¿Éú £¨2026ÄêÈëѧ£©
ÒѾÓÐ2È˻ظ´
349ҩѧר˶105500Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
298Çóµ÷¼ÁÒ»Ö¾Ô¸Öк£Ñó
ÒѾÓÐ3È˻ظ´
ҩѧµ÷¼ÁÉêÇë×Ô¼öÐÅ£¬Ò»Ö¾Ô¸ÖÐÄÏ´óѧ
ÒѾÓÐ1È˻ظ´
ҩѧ349ר˶Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
¡¶×óÒÒÀÎ÷̹עÉäÒºÖÆ±¸¹¤ÒÕÑо¿¡¢ÖÊÁ¿¿ØÖƺÍÎȶ¨ÐÔÑо¿¡·ÏÂÔØ
ÒѾÓÐ1È˻ظ´
shinaiyue
ͳæ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 62.4
- Ìû×Ó: 242
- ÔÚÏß: 10.5Сʱ
- ³æºÅ: 909677
- ×¢²á: 2009-11-22
2Â¥2010-01-20 20:07:57














»Ø¸´´ËÂ¥
10